Wang Xiaoying, Jian Xiao, Dou Jun, Wei Zicheng, Zhao Fengshu
Wuxi School of Medicine, Jiangnan University, Wuxi, People's Republic of China.
Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Cancer Manag Res. 2020 Jan 29;12:663-673. doi: 10.2147/CMAR.S229156. eCollection 2020.
The microtubule actin cross-linking factor 1 (MACF1) is involved in cellular migration, adhesion, and invasion processes. Its abnormal expression initiates tumor cell proliferation and metastasis in numerous cancer types.
In this study, we utilized short hair-pin RNA interference of MACF1 to assess the inhibitory effects on the metastatic potential of B16F10 melanoma cells both in vitro and in vivo a mouse model.
The MACF1 expression was increased in B16F10 cells-induced tumor tissues; while the down-regulation of MACF1 impacted the B16F10 melanoma cell metastatic behavior by decreasing the ability of colony formation and invasion in vitro as well as inhibiting B16F10 cells-induced tumor growth and lung metastasis in vivo. The results of Western blot and immunohistochemistry indicated that the expression of E-cadherin and Smad-7 was significantly increased whereas the expression of N-cadherin and TGF-β1 was significantly decreased in tumor tissue of mice challenged with the B16F10/MACF1-RNAi cells when compared with the B16F10 cells challenged mice.
The data presented in this study demonstrated that down-regulated MACF1 expression decreased B16F10 melanoma metastasis in mice by inhibiting the epithelial to mesenchymal transition program. Thus, MACF1 may be a novel target for melanoma therapy.
微管肌动蛋白交联因子1(MACF1)参与细胞迁移、黏附和侵袭过程。其异常表达在多种癌症类型中引发肿瘤细胞增殖和转移。
在本研究中,我们利用MACF1的短发夹RNA干扰来评估对B16F10黑色素瘤细胞体外和体内(小鼠模型)转移潜能的抑制作用。
在B16F10细胞诱导的肿瘤组织中MACF1表达增加;而MACF1的下调通过降低体外集落形成和侵袭能力以及抑制体内B16F10细胞诱导的肿瘤生长和肺转移来影响B16F10黑色素瘤细胞的转移行为。蛋白质免疫印迹和免疫组织化学结果表明,与用B16F10细胞攻击的小鼠相比,用B16F10/MACF1-RNAi细胞攻击的小鼠肿瘤组织中E-钙黏蛋白和Smad-7的表达显著增加,而N-钙黏蛋白和TGF-β1的表达显著降低。
本研究提供的数据表明,下调MACF1表达通过抑制上皮-间质转化程序降低了小鼠B16F10黑色素瘤的转移。因此,MACF1可能是黑色素瘤治疗的一个新靶点。